决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Correction to: Induced CD20 Expression on B-Cell Malignant Cells Heightened the Cytotoxic Activity of Chimeric Antigen Receptor Engineered T Cells, by Xu et al. Hum Gene Ther 2019;30(4):497-510. DOI: 10.1089/hum.2018.119.
Correction to: Induced CD20 Expression on B-Cell Malignant Cells Heightened the Cytotoxic Activity of Chimeric Antigen Receptor Engineered T Cells, by Xu et al. Hum Gene Ther 2019;30(4):497-510. DOI: 10.1089/hum.2018.119.
这条还没有中文摘要(正在补翻译)。 可以先展开下面的英文原文,或点最下面的「在 PubMed 查看」读原文献。
MEMBER ACCOUNT
登录成功会直接打开下一页。